To read the full story, subscribe or sign in.

Studies detail long-term hepatitis B viral suppression with telbivudine

Oct. 31, 2006

No Comments

BioWorld Science Conferences Gastrointestinal

Today's news in brief

BioWorld

BioWorld briefs for Oct. 30, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for October 30, 2024.

By the numbers: US leads charge of cell and gene therapies

BioWorld

U.S. biotechs and regulators ushered in the era of gene therapy in 2023, experts at Bio Japan said, but medical reform is needed to pave the way for the “year of...

Nanocube’s nanorobots to revolutionize cancer diagnosis, treatment

BioWorld MedTech

Nanocube Health Ltd. is developing accessible, low-cost nanorobots that could revolutionize diagnosis and treatment of hard-to-diagnose cancers, with pancreatic...

Merck’s clesrovimab tortoise to Beyfortus in RSV race?

BioWorld

Wall Street promptly began trying to weigh the compound’s marketplace odds after Merck & Co. Inc. detailed positive data from the phase IIb/III trial known as...

Upgrade your daily dose of biopharma and medtech news

Studies detail long-term hepatitis B viral suppression with telbivudine